Basic Science Review: Nitric Oxide—Releasing Prosthetic Materials

Varu, Vinit N.; Tsihlis, Nick D.; Kibbe, Melina R.

doi:10.1177/1538574408322752

Cited by 40 publications

(53 citation statements)

References 63 publications

(108 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Inhaled NO gas diffuses rapidly across the alveolar-capillary membrane and activates sGC in the subjacent smooth muscle cells in the pulmonary vasculature (69). N-diazeniumdiolates (NONOates) are NO donors that are synthesized by reacting primary or secondary amines with NO gas at high pressure and low temperatures; hydrolysis causes spontaneous decomposition under physiological conditions and releases NO (70–72). Nitric oxide (as N 2 O 3 or − ONOO) can react with thiols in vivo to form S-nitrosothiols, such as S-nitrosocysteine and S-nitrosoglutathione (73).…”

Section: Preparationsmentioning

confidence: 99%

The Role of Nitroglycerin and Other Nitrogen Oxides in Cardiovascular Therapeutics

Divakaran

Loscalzo

2017

Journal of the American College of Cardiology

119

View full text Add to dashboard Cite

The use of nitroglycerin in the treatment of angina pectoris began not long after its original synthesis in 1847. Since then, the discovery of nitric oxide as a biological effector and better understanding of its roles in vasodilation, cell permeability, platelet function, inflammation, and other vascular processes have advanced our knowledge of the hemodynamic (mostly mediated through vasodilation of capacitance and conductance arteries) and non-hemodynamic effects of organic nitrate therapy, via both nitric oxide-dependent and independent mechanisms. Nitrates are rapidly absorbed from mucous membranes, the gastrointestinal tract, and the skin, and, thus, nitroglycerin is available in several preparations for delivery via several routes: oral tablets, sublingual tablets, buccal tablets, sublingual spray, transdermal ointment, and transdermal patch; it is also available in intravenous formulations. The organic nitrates are commonly used in the treatment of cardiovascular disease, but clinical data limit their use mostly to the treatment of angina. They are also used in the treatment of subsets of patients with heart failure and pulmonary hypertension. One major problem with the use of nitrates is the development of tolerance. Although several agents have been studied for use in the prevention of nitrate tolerance, none are currently recommended owing to a paucity of supportive clinical data. Only one method of preventing nitrate tolerance remains widely accepted: the use of a dosing strategy that provides an interval of no or low nitrate exposure during each 24-hour period. Nitric oxide’s important role in several cardiovascular disease mechanisms continues to drive research toward finding novel ways to affect both endogenous and exogenous sources of this key molecular mediator.

show abstract

Section: Preparationsmentioning

confidence: 99%

The Role of Nitroglycerin and Other Nitrogen Oxides in Cardiovascular Therapeutics

Divakaran

Loscalzo

2017

Journal of the American College of Cardiology

119

View full text Add to dashboard Cite

show abstract

“…These compounds are known as NO donors. Of these, nitroglycerin might be the most prominent one, which can release one molar equivalent of NO by trinitrate species conversion upon inhalation, oral or transdermal administration targeting mitochondrial enzymes as described in Section 2.1 [50,112]. It is one of the low molecular weight (LMW) organic nitrate donors commonly used as vasodilator drugs in modern medicine for delivery of NO.…”

Section: Mechanisms Of Nitric Oxide Producing Materialsmentioning

confidence: 98%

“…The predictable first-order release kinetics of NO depend on the exact atomic structure and amount of amine precursor, which can vary from short time periods (seconds) to days or even weeks due to hydrogen bonding stabilization from additional amines. Furthermore, by specific modification in the chemistry of NONOates, local NO release at target sites might be achieved using a cell/tissue-specific enzyme or metabolitesas cleavable linkers [112]. However there are concerns about toxicity issues of nitrosamines, which are formed by hydrophilic diazeniumdiolates leaching from the polymer matrix [116].…”

Section: Mechanisms Of Nitric Oxide Producing Materialsmentioning

confidence: 99%

“…It is one of the low molecular weight (LMW) organic nitrate donors commonly used as vasodilator drugs in modern medicine for delivery of NO. Nitroglycerin or GTN can reduce anginal chest pain and hypertension in CVD treatment [50,112]. However, lack of specificity and decreased tolerance levels after prolonged use limit their applications as NO donors.…”

Section: Mechanisms Of Nitric Oxide Producing Materialsmentioning

confidence: 99%

See 1 more Smart Citation

Nitric oxide based strategies for applications of biomedical devices

Yang

et al. 2015

Biosurface and Biotribology

View full text Add to dashboard Cite

Since the first report describing nitric oxide (NO) in the mid-1980s, research efforts have been devoted to elucidating the pathway of NO generation and the mechanism of NO function in vivo. The worldwide expansion of NO investigations have helped advance progress in biomedical device applications of NO-based strategies for cardiovascular devices, wound healing and antimicrobial agents, including recent in vivo investigations. Here we describe the general concepts of NO discovery, mechanisms of NO synthesis in vivo and NO producing materials. Both design strategies and results are discussed and compared in release kinetics, NO dose and biological effects, with the aim of providing foundations for the development of new NO-based therapeutics. & 2015 Southwest Jiaotong University. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

show abstract

“…These NO donors are incorporated into materials either by blending discrete NO donors within polymeric films, or by covalently attaching them to polymer backbones and/or to the inorganic polymeric filler particles that are often employed to enhance the strength of biomedical polymers (e.g., fumed silica or titanium dioxide). [28] N -diazeniumdiolates[26, 29, 30] and S -nitrosothiols[30–32] are commonly used to prepare NO releasing polymeric matrices for improved biocompatibility of blood-contacting medical devices. The N -diazeniumdiolates are generally synthesized by reaction of amines with NO gas to form relatively stable compounds that release NO when in contact with bodily fluids through proton or thermally driven mechanisms.…”

Section: Introductionmentioning

confidence: 99%

Inhibition of bacterial adhesion and biofilm formation by dual functional textured and nitric oxide releasing surfaces

Meyerhoff

et al. 2017

Acta Biomaterialia

View full text Add to dashboard Cite

In separate prior studies, physical topographic surface modification or nitric oxide (NO) release has been demonstrated to each be an effective approach to inhibit and control bacterial adhesion and biofilm formation on polymeric surfaces. Such approaches can prevent biomaterial-associated infection without causing the antibiotic resistance of the strain. In this work, both techniques were successfully integrated and applied to a polyurethane (PU) biomaterial surface that bears ordered pillar topographies (400/400 nm and 500/500 nm patterns) at the top surface and a S-nitroso-N-acetylpenicillamine (SNAP, NO donor) doped sub-layer in the middle, via a soft lithography two-stage replication process. Upon placing the SNAP textured PU films into PBS at 37°C, the decomposition of SNAP within polymer film initiates NO release with a lifetime of up to 10 days at flux levels > 0.5 ×10−10 mol min−1 cm−2 for a textured polyurethane layer containing 15 wt% SNAP. The textured surface reduces the accessible surface area and the opportunity of bacteria-surface interaction, while the NO release from the same surface further inhibits bacterial growth and biofilm formation. Such dual functionality surfaces are shown to provide a synergistic effect on inhibition of Staphylococcus epidermidis bacterial adhesion that is significantly greater than the inhibition of bacterial adhesion achieved by either single treatment approach alone. Longer term experiments to observe biofilm formation demonstrate that the SNAP doped-textured PU surface can inhibit the biofilm formation for > 28 d and provide a practical approach to improve the biocompatibility of current biomimetic biomaterials and thereby reduce the risk of pathogenic infection.

show abstract

Basic Science Review: Nitric Oxide—Releasing Prosthetic Materials

Cited by 40 publications

References 63 publications

The Role of Nitroglycerin and Other Nitrogen Oxides in Cardiovascular Therapeutics

The Role of Nitroglycerin and Other Nitrogen Oxides in Cardiovascular Therapeutics

Nitric oxide based strategies for applications of biomedical devices

Inhibition of bacterial adhesion and biofilm formation by dual functional textured and nitric oxide releasing surfaces

Contact Info

Product

Resources

About